Pneumagen is developing glycan targeted carbohydrate binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs).

Latest news

May 27, 2020
Pneumagen Announces £4m fundraising and Commits to Clinical Trial Development for COVID-19
May 8, 2020
Pneumagen Ltd’s Recent COVID-19 Data Covered by BBC’s "The Nine"
Apr 28, 2020
Pneumagen Ltd Announces Positive Anti–Viral Activity for Novel Glycan Approach in Preventing COVID–19 Infections

Meet the team